SavedAdd your journal

Journals / Adıyaman Üniversitesi Sağlık Bilimleri Dergisi / 2026 / Cilt: 12 Sayı: 1

The role of surgery type in breast cancer patients with recurrent breast cancer receiving neoadjuvant chemotherapy

Neoadjuvan kemoterapi alan nüks meme kanserli hastalarda cerrahi tipinin rolü

Erdoğan Selçuk Şeber(TEKIRDAG NAMIK KEMAL UNIVERSITY)0000-0001-9081-2405
Özge Yalıcı(NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0002-0260-7511
Pages
1–9
Publication Date
2026-04-23
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recurrence-free survival (RFS), overall survival (OS), and associated factors were evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To assess the impact of surgical approach on recurrence and survival in breast cancer patients with recurrence post-neoadjuvant chemotherapy (NACT).
📊
Key Findings & Data:Materials and Methods: A retrospective analysis included 108 female patients (≥18 years) who completed NACT (2010–2024) and developed recurrence.
💡
Conclusion & Impact:Recurrence-free survival (RFS), overall survival (OS), and associated factors were evaluated.
🔬Design:Araştırma Makalesi
📍Scope:2010–2024 Verileri
⚙️Variables:Meme kanseri · Neoadjuvan kemoterapi · Cerrahi yaklaşım

Abstract

Aim: To assess the impact of surgical approach on recurrence and survival in breast cancer patients with recurrence post-neoadjuvant chemotherapy (NACT). Materials and Methods: A retrospective analysis included 108 female patients (≥18 years) who completed NACT (2010–2024) and developed recurrence. Patients underwent breast-conserving surgery (BCS) or mastectomy (MX), with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Recurrence-free survival (RFS), overall survival (OS), and associated factors were evaluated. Results: Among 108 patients (68 BCS, 40 MX, 18 SLNB, 90 ALND), the median RFS was 23.67 months (BCS: 24.53 vs. MX: 18.97; p=0.65; SLNB: 25.87 vs. ALND: 22.30; p=0.65). Five‑year RFS rates were 1% and 10% in the two groups, respectively. The median OS was 55.57 months (BCS: 56.07 vs. MX: 50.43; p=0.607; SLNB: 75.90 vs. ALND: 48.70; p=0.019). Molecular subtype (HR=2.12, p<0.001) and axillary surgery type (HR=4.41, p=0.005) were independent predictors of OS. The mean follow‑up duration was 59.96 ± 3.62 months. Conclusion: BCS and MX provide comparable RFS and OS in patients with recurrence after NACT. SLNB is associated with significantly improved OS compared with ALND, underscoring the importance of tailoring axillary management to tumor biology and patient-specific factors.

Özet

Amaç: Neoadjuvan kemoterapi (NACT) sonrası nüks eden meme kanseri hastalarında cerrahi yaklaşımın nüks ve sağkalım üzerindeki etkisini değerlendirmek. Gereç ve Yöntem: Retrospektif analiz, NACT'yi tamamlayan (2010-2024) ve nüks gelişen 108 kadın hastayı (≥18 yaş) içermektedir. Hastalar, sentinel lenf nodu biyopsisi (SLNB) veya aksiller lenf nodu diseksiyonu (ALND) ile meme koruyucu cerrahi (BCS) veya mastektomi (MX) geçirdi. Nükssüz sağkalım (RFS), genel sağkalım (OS) ve ilişkili faktörler değerlendirildi. Bulgular: Toplam 108 hastanın (68 MKC, 40 MX, 18 SLNB, 90 ALND) medyan RFS süresi 23,67 aydı (MKC: 24,53 vs. MX: 18,97; p=0,65; SLNB: 25,87 vs. ALND: 22,30; p=0,65). Beş yıllık RFS oranları iki grupta sırasıyla %1 ve %10 idi. Medyan OS 55,57 ay olarak bulundu (MKC: 56,07 vs. MX: 50,43; p=0,607; SLNB: 75,90 vs. ALND: 48,70; p=0,019). Moleküler alt tip (HR=2.12, p<0.001) ve aksiller cerrahi tipi (HR=4,41, p=0,005) OS için bağımsız belirleyicilerdi. Ortalama takip süresi 59,96 ± 3,62 aydı. Sonuç: MKC ve MX, NAKT sonrası nüks gelişen hastalarda benzer RFS ve OS sonuçları sağlamaktadır. SLNB’nin ALND’ye kıyasla anlamlı derecede daha iyi OS ile ilişkili olması, aksiller cerrahi yaklaşımının tümör biyolojisi ve hasta özelliklerine göre kişiselleştirilmesinin önemini vurgulamaktadır.

🔖

Cite This Article

Şeber, E. S., Yalıcı, Ö. (2026). The role of surgery type in breast cancer patients with recurrent breast cancer receiving neoadjuvant chemotherapy. Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 Sayı: 1, 1–9. https://doi.org/10.30569/adiyamansaglik.1738262

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
  2. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575. doi:10.1056/NEJMoa020128
  3. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575. doi:10.1001/jama.2011.90
  4. Zwakman M, Tan A, Boersma C, et al. Long-term quality of life and aesthetic outcomes after breast conserving surgery in patients with breast cancer. Eur J Surg Oncol. 2022;48(8):1692-1698. doi:10.1016/j.ejso.2022.03.001
  5. Rajan KK, Fairhurst K, Birkbeck B, et al. Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis. BJS Open. 2024;8(3):zrae040. doi:10.1093/bjsopen/zrae040
  6. Vila J, Mittendorf EA, Farante G, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2017;24(7):1941-1947. doi:10.1245/s10434-017-5791-6
  7. Ahn JH, Choi SB, Park JM, et al. Level of combined estrogen and progesterone receptor expression determines the eligibility for adjuvant endocrine therapy in breast cancer patients. Cancers (Basel). 2021;13(19):5007. doi:10.3390/cancers13195007
  8. Liu YL, Saraf A, Lee SM, et al. Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016;157(3):555-564. doi:10.1007/s10549-016-3836-9
  9. Al-Gaithy ZK, Yaghmoor BE, Koumu MI, et al. Trends of mastectomy and breast-conserving surgery and related factors in female breast cancer patients treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017: a retrospective cohort study. Ann Med Surg (Lond). 2019;41:47-52. doi:10.1016/j.amsu.2019.03.012
  10. Çiftci F. The role of breast-conserving surgery in the treatment of early-stage breast cancer. Dicle Med J. 2020;47(4):852-858. doi:10.5798/dicletip.850178
  11. Liu J, Zheng X, Lin S, Han H, Xu C. Breast conserving therapy for central breast cancer in the United States. BMC Surg. 2022;22(1):31. doi:10.1186/s12893-022-01481-0
  12. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-2685. doi:10.1200/JCO.1998.16.8.2672
  13. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224-4237. doi:10.1200/JCO.2001.19.22.4224
  14. Cavalcante FP, Zerwes FP, Alcantara R, et al. Oncological outcomes of breast-conserving surgery versus mastectomy following neoadjuvant chemotherapy in a contemporary multicenter cohort. Sci Rep. 2025;15(1):9032. doi:10.1038/s41598-025-59542-2
  15. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. doi:10.1016/S0140-6736(11)61629-2
  16. Schoppmann SF, Bayer G, Aumayr K, et al; Austrian Breast and Colorectal Cancer Study Group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240(2):306-312. doi:10.1097/01.sla.0000133355.48672.22
  17. Cavdar E, Iriagac Y, Karaboyun K, Avci O. Prognostic role of lymphovascular invasion and perineural invasion in breast cancer treated with neoadjuvant chemotherapy. UHOD. 2022;32(3):141-149. doi:10.4999/uhod.226300
  18. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539-552. doi:10.1007/s10549-013-2560-8
  19. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;317(16):1667-1676. doi:10.1001/jama.2017.2836
  20. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-1310. doi:10.1016/S1470-2045(14)70444-8
  21. Ling DC, Iarrobino NA, Champ CE, Soran A, Beriwal S. Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy. Adv Radiat Oncol. 2020;5(2):163-170. doi:10.1016/j.adro.2019.09.006